Capmatinib
Sign in to save this workspacePrimary targets: C_MET · FDA status: FDA Approved
Selectivity scorecard
KISS
99.75
Gini
0.582
CATDS
0.046
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Capmatinib. Strongest target: C_MET at 99.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | C_MET | 99.5% | 0.5% |
| 2 | EGFR | 63.1% | 36.9% |
| 3 | ROS_ROS1 | 60.2% | 39.8% |
| 4 | JAK3 | 53.5% | 46.5% |
| 5 | RON_MST1R | 26.4% | 73.6% |
| 6 | MST3_STK24 | 22.2% | 77.8% |
| 7 | SRPK2 | 20.8% | 79.2% |
| 8 | HASPIN | 20.7% | 79.3% |
| 9 | AXL | 20.1% | 79.9% |
| 10 | MYLK4 | 19.7% | 80.3% |
| 11 | RIPK2 | 19.3% | 80.7% |
| 12 | PDGFRB | 17.9% | 82.1% |
| 13 | ERBB4_HER4 | 17.3% | 82.7% |
| 14 | EIF2AK2 | 17.0% | 83.0% |
| 15 | STK32B_YANK2 | 16.4% | 83.6% |
| 16 | ABL2_ARG | 15.9% | 84.1% |
| 17 | CAMKK2 | 15.8% | 84.2% |
| 18 | PKN3_PRK3 | 15.7% | 84.3% |
| 19 | PDK3_PDHK3 | 15.4% | 84.6% |
| 20 | CAMK1D | 15.1% | 84.9% |
Selectivity landscape
Where Capmatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Capmatinib.
Annotations
Sign in to read and post annotations.
Loading…